Managing diabetic dyslipidemia: aggressive approach.

نویسنده

  • Kelly Anne Spratt
چکیده

The United States is experiencing a marked increase in rates of diabetes mellitus and metabolic syndrome, almost certainly in part due to the increase in obesity rates. This phenomenon is likely to also result in an increased risk of coronary artery disease as risk factors increase exponentially. This article defines diabetic dyslipidemia, the rationale for aggressive treatment, and options for ongoing management, including nonpharmacologic therapy and medications, alone or in combination, for management of all aspects of the lipid profile.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia THE DIABETES ATORVASTATIN LIPID INTERVENTION (DALI) STUDY GROUP

OBJECTIVE — In patients with type 2 diabetes, intensive glucose regulation, although effective for microangiopathy, has not been shown to have unambiguous preventive effects on the occurrence of cardiovascular disease. Patients with diabetes show a characteristic dyslipidemia (high triglyceride level, low HDL cholesterol level). Aggressive reduction of triglycerides might be an effective method...

متن کامل

Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria.

BACKGROUND Dyslipidemia has been identified as a risk factor for the development and progression of diabetic renal disease. OBJECTIVE This study was done to determine the prevalence of dyslipidemia among diabetic patients with overt nephropathy. MATERIALS AND METHODS A total of 72 diabetic patients with overt diabetic nephropathy and 36 age- and sex-matched normoalbuminuric diabetic patient...

متن کامل

Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.

OBJECTIVE Endothelial dysfunction is considered an important early marker of atherosclerosis and cardiovascular risk and is currently used as a surrogate end point for cardiovascular risk in clinical trials. Type 2 diabetic patients show a characteristic dyslipidemia. Aggressive lipid lowering might be an effective method to improve endothelial function in these patients. RESEARCH DESIGN AND ...

متن کامل

Role of FFA in the Pathogenesis of Insulin Resistance, Diabetes, and Dyslipidemia

duals with diabetes, accounting for 80% of all mortality. Approximately 75% of deaths result from coronary atherosclerosis and 25% from cerebral or peripheral arterial disease. Greater than 75% of hospitalizations for diabetic complications are due to atherosclerosis (1). Mortality rates for ischemic heart disease are twoto fourfold greater for individuals with diabetes compared to those withou...

متن کامل

Dyslipidemias in type 2 diabetes mellitus patients in Nnewi South-East Nigeria.

BACKGROUND Dyslipidemia has been noted to play an integral role in the pathogenesis and progression of micro and macrovascular complications in diabetes mellitus patients. The complications exemplified by renal vascular and cardiovascular disease cause the most morbidity and mortality in this group of patients. OBJECTIVE This study is aimed at understanding the pattern of dyslipidemia among t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of the American Osteopathic Association

دوره 109 5 Suppl  شماره 

صفحات  -

تاریخ انتشار 2009